Andy divya (17 résultats)

- Couverture souple
Vendeur : California Books, Miami, FL, Etats-UnisCalifornia Books
Contacter le vendeurVendeur avec une évaluation de 5 étoilesEtat: Neuf
EUR 253,19
EUR 2,72 expéditionExpédition nationale : Etats-UnisQuantité disponible : Plus de 20 disponibles
Etat : New.

- Couverture rigide
Vendeur : California Books, Miami, FL, Etats-UnisCalifornia Books
Contacter le vendeurVendeur avec une évaluation de 5 étoilesEtat: Neuf
EUR 299,90
EUR 2,72 expéditionExpédition nationale : Etats-UnisQuantité disponible : Plus de 20 disponibles
Etat : New.

- Couverture rigide
Vendeur : Home-set, Mannheim, AllemagneHome-set
Contacter le vendeurVendeur avec une évaluation de 5 étoilesEtat: Neuf
EUR 372,25
EUR 60,98 expéditionExpédition depuis Allemagne vers Etats-UnisQuantité disponible : 2 disponibles
Gebundene Ausgabe. Etat : Neu. Gene and cell therapy is entering a new phase, one where artificial intelligence is bringing precision and predictability to editing systems that were once largely trial-and-error. From CRISPR-Cas genome editing to emerging techniques like epigenome modulation and mitochondrial genome correction, machine learning and deep learning are increasingly guiding how these tools are designed and scaled. AI is helping minimize off-target effects, improve manufacturing predictability, and build in the kind of explainability and bias mitigation that safety and regulatory approval demand. As these technologies move closer to widespread clinical use, the field needs a framework that ties computational innovation directly to therapeutic application, rather than treating AI and biomedicine as separate conversations. This convergence of computational innovation and biological engineering marks one of the most consequential shifts in modern therapeutic science. AI-Driven Innovations in Genome, Epigenome, and Mitochondrial Therapies provides state-of-the-art, data-driven methodologies for designing, optimizing, and validating safer, more precise, and scalable gene and cell therapies. By connecting concrete biomedical applications with benchmarked computational pipelines and structured frameworks for transparent, accountable AI governance, this book equips researchers and practitioners to navigate discovery, preclinical validation, clinical translation, and lifecycle risk management. Covering topics such as genome-enabled precision wound care, mitochondrial mutation detection, and mitochondrial editing, this book is an excellent academic resource for graduate and doctoral students, biomedical researchers, AI and machine learning specialists, bioinformaticians, regulatory affairs professionals, policymakers, and more. Sprache: Englisch Gewicht in Gramm: 1119.…

- Couverture souple
- impression à la demande
Vendeur : PBShop.store UK, Fairford, GLOS, Royaume-UniPBShop.store UK
Contacter le vendeurVendeur avec une évaluation de 5 étoilesEtat: Neuf
EUR 207,54
EUR 7,04 expéditionExpédition depuis Royaume-Uni vers Etats-UnisQuantité disponible : Plus de 20 disponibles
PAP. Etat : New. New Book. Delivered from our UK warehouse in 4 to 14 business days. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.

- Couverture souple
- impression à la demande
Vendeur : PBShop.store US, Wood Dale, IL, Etats-UnisPBShop.store US
Contacter le vendeurVendeur avec une évaluation de 5 étoilesEtat: Neuf
EUR 219,17
Frais de port gratuitsExpédition nationale : Etats-UnisQuantité disponible : Plus de 20 disponibles
PAP. Etat : New. New Book. Shipped from UK. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.

- Couverture souple
- impression à la demande
Vendeur : Grand Eagle Retail, Bensenville, IL, Etats-UnisGrand Eagle Retail
Contacter le vendeurVendeur avec une évaluation de 5 étoilesEtat: Neuf
EUR 254,13
Frais de port gratuitsExpédition nationale : Etats-UnisQuantité disponible : 1 disponible
Paperback. Etat : new. Paperback. Gene and cell therapy is entering a new phase, one where artificial intelligence is bringing precision and predictability to editing systems that were once largely trial-and-error. From CRISPR-Cas genome editing to emerging techniques like epigenome modulation and mitochondrial genome correction, machine learning and deep learning are increasingly guiding how these tools are designed and scaled. AI is helping minimize off-target effects, improve manufacturing predictability, and build in the kind of explainability and bias mitigation that safety and regulatory approval demand. As these technologies move closer to widespread clinical use, the field needs a framework that ties computational innovation directly to therapeutic application, rather than treating AI and biomedicine as separate conversations. This convergence of computational innovation and biological engineering marks one of the most consequential shifts in modern therapeutic science. AI-Driven Innovations in Genome, Epigenome, and Mitochondrial Therapies provides state-of-the-art, data-driven methodologies for designing, optimizing, and validating safer, more precise, and scalable gene and cell therapies. By connecting concrete biomedical applications with benchmarked computational pipelines and structured frameworks for transparent, accountable AI governance, this book equips researchers and practitioners to navigate discovery, preclinical validation, clinical translation, and lifecycle risk management. Covering topics such as genome-enabled precision wound care, mitochondrial mutation detection, and mitochondrial editing, this book is an excellent academic resource for graduate and doctoral students, biomedical researchers, AI and machine learning specialists, bioinformaticians, regulatory affairs professionals, policymakers, and more. This item is printed on demand. Shipping may be from multiple locations in the US or from the UK, depending on stock availability.…

- Couverture rigide
- impression à la demande
Vendeur : PBShop.store UK, Fairford, GLOS, Royaume-UniPBShop.store UK
Contacter le vendeurVendeur avec une évaluation de 5 étoilesEtat: Neuf
EUR 245,22
EUR 8,10 expéditionExpédition depuis Royaume-Uni vers Etats-UnisQuantité disponible : Plus de 20 disponibles
HRD. Etat : New. New Book. Delivered from our UK warehouse in 4 to 14 business days. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.

- Couverture rigide
- impression à la demande
Vendeur : PBShop.store US, Wood Dale, IL, Etats-UnisPBShop.store US
Contacter le vendeurVendeur avec une évaluation de 5 étoilesEtat: Neuf
EUR 259,21
Frais de port gratuitsExpédition nationale : Etats-UnisQuantité disponible : Plus de 20 disponibles
HRD. Etat : New. New Book. Shipped from UK. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.

- Couverture souple
- impression à la demande
Vendeur : CitiRetail, Stevenage, Royaume-UniCitiRetail
Contacter le vendeurVendeur avec une évaluation de 5 étoilesEtat: Neuf
EUR 217,91
EUR 44,35 expéditionExpédition depuis Royaume-Uni vers Etats-UnisQuantité disponible : 1 disponible
Paperback. Etat : new. Paperback. Gene and cell therapy is entering a new phase, one where artificial intelligence is bringing precision and predictability to editing systems that were once largely trial-and-error. From CRISPR-Cas genome editing to emerging techniques like epigenome modulation and mitochondrial genome correction, machine learning and deep learning are increasingly guiding how these tools are designed and scaled. AI is helping minimize off-target effects, improve manufacturing predictability, and build in the kind of explainability and bias mitigation that safety and regulatory approval demand. As these technologies move closer to widespread clinical use, the field needs a framework that ties computational innovation directly to therapeutic application, rather than treating AI and biomedicine as separate conversations. This convergence of computational innovation and biological engineering marks one of the most consequential shifts in modern therapeutic science. AI-Driven Innovations in Genome, Epigenome, and Mitochondrial Therapies provides state-of-the-art, data-driven methodologies for designing, optimizing, and validating safer, more precise, and scalable gene and cell therapies. By connecting concrete biomedical applications with benchmarked computational pipelines and structured frameworks for transparent, accountable AI governance, this book equips researchers and practitioners to navigate discovery, preclinical validation, clinical translation, and lifecycle risk management. Covering topics such as genome-enabled precision wound care, mitochondrial mutation detection, and mitochondrial editing, this book is an excellent academic resource for graduate and doctoral students, biomedical researchers, AI and machine learning specialists, bioinformaticians, regulatory affairs professionals, policymakers, and more. This item is printed on demand. Shipping may be from our UK warehouse or from our Australian or US warehouses, depending on stock availability.…

- Couverture rigide
- impression à la demande
Vendeur : Grand Eagle Retail, Bensenville, IL, Etats-UnisGrand Eagle Retail
Contacter le vendeurVendeur avec une évaluation de 5 étoilesEtat: Neuf
EUR 296,80
Frais de port gratuitsExpédition nationale : Etats-UnisQuantité disponible : 1 disponible
Hardcover. Etat : new. Hardcover. Gene and cell therapy is entering a new phase, one where artificial intelligence is bringing precision and predictability to editing systems that were once largely trial-and-error. From CRISPR-Cas genome editing to emerging techniques like epigenome modulation and mitochondrial genome correction, machine learning and deep learning are increasingly guiding how these tools are designed and scaled. AI is helping minimize off-target effects, improve manufacturing predictability, and build in the kind of explainability and bias mitigation that safety and regulatory approval demand. As these technologies move closer to widespread clinical use, the field needs a framework that ties computational innovation directly to therapeutic application, rather than treating AI and biomedicine as separate conversations. This convergence of computational innovation and biological engineering marks one of the most consequential shifts in modern therapeutic science. AI-Driven Innovations in Genome, Epigenome, and Mitochondrial Therapies provides state-of-the-art, data-driven methodologies for designing, optimizing, and validating safer, more precise, and scalable gene and cell therapies. By connecting concrete biomedical applications with benchmarked computational pipelines and structured frameworks for transparent, accountable AI governance, this book equips researchers and practitioners to navigate discovery, preclinical validation, clinical translation, and lifecycle risk management. Covering topics such as genome-enabled precision wound care, mitochondrial mutation detection, and mitochondrial editing, this book is an excellent academic resource for graduate and doctoral students, biomedical researchers, AI and machine learning specialists, bioinformaticians, regulatory affairs professionals, policymakers, and more. This item is printed on demand. Shipping may be from multiple locations in the US or from the UK, depending on stock availability.…

- Couverture rigide
- impression à la demande
Vendeur : CitiRetail, Stevenage, Royaume-UniCitiRetail
Contacter le vendeurVendeur avec une évaluation de 5 étoilesEtat: Neuf
EUR 256,81
EUR 44,35 expéditionExpédition depuis Royaume-Uni vers Etats-UnisQuantité disponible : 1 disponible
Hardcover. Etat : new. Hardcover. Gene and cell therapy is entering a new phase, one where artificial intelligence is bringing precision and predictability to editing systems that were once largely trial-and-error. From CRISPR-Cas genome editing to emerging techniques like epigenome modulation and mitochondrial genome correction, machine learning and deep learning are increasingly guiding how these tools are designed and scaled. AI is helping minimize off-target effects, improve manufacturing predictability, and build in the kind of explainability and bias mitigation that safety and regulatory approval demand. As these technologies move closer to widespread clinical use, the field needs a framework that ties computational innovation directly to therapeutic application, rather than treating AI and biomedicine as separate conversations. This convergence of computational innovation and biological engineering marks one of the most consequential shifts in modern therapeutic science. AI-Driven Innovations in Genome, Epigenome, and Mitochondrial Therapies provides state-of-the-art, data-driven methodologies for designing, optimizing, and validating safer, more precise, and scalable gene and cell therapies. By connecting concrete biomedical applications with benchmarked computational pipelines and structured frameworks for transparent, accountable AI governance, this book equips researchers and practitioners to navigate discovery, preclinical validation, clinical translation, and lifecycle risk management. Covering topics such as genome-enabled precision wound care, mitochondrial mutation detection, and mitochondrial editing, this book is an excellent academic resource for graduate and doctoral students, biomedical researchers, AI and machine learning specialists, bioinformaticians, regulatory affairs professionals, policymakers, and more. This item is printed on demand. Shipping may be from our UK warehouse or from our Australian or US warehouses, depending on stock availability.…

- Couverture souple
- impression à la demande
Vendeur : AussieBookSeller, Truganina, VIC, AustralieAussieBookSeller
Contacter le vendeurVendeur avec une évaluation de 5 étoilesEtat: Neuf
EUR 281,59
EUR 33,56 expéditionExpédition depuis Australie vers Etats-UnisQuantité disponible : 1 disponible
Paperback. Etat : new. Paperback. Gene and cell therapy is entering a new phase, one where artificial intelligence is bringing precision and predictability to editing systems that were once largely trial-and-error. From CRISPR-Cas genome editing to emerging techniques like epigenome modulation and mitochondrial genome correction, machine learning and deep learning are increasingly guiding how these tools are designed and scaled. AI is helping minimize off-target effects, improve manufacturing predictability, and build in the kind of explainability and bias mitigation that safety and regulatory approval demand. As these technologies move closer to widespread clinical use, the field needs a framework that ties computational innovation directly to therapeutic application, rather than treating AI and biomedicine as separate conversations. This convergence of computational innovation and biological engineering marks one of the most consequential shifts in modern therapeutic science. AI-Driven Innovations in Genome, Epigenome, and Mitochondrial Therapies provides state-of-the-art, data-driven methodologies for designing, optimizing, and validating safer, more precise, and scalable gene and cell therapies. By connecting concrete biomedical applications with benchmarked computational pipelines and structured frameworks for transparent, accountable AI governance, this book equips researchers and practitioners to navigate discovery, preclinical validation, clinical translation, and lifecycle risk management. Covering topics such as genome-enabled precision wound care, mitochondrial mutation detection, and mitochondrial editing, this book is an excellent academic resource for graduate and doctoral students, biomedical researchers, AI and machine learning specialists, bioinformaticians, regulatory affairs professionals, policymakers, and more. This item is printed on demand. Shipping may be from our Sydney, NSW warehouse or from our UK or US warehouse, depending on stock availability.…

- Couverture souple
- impression à la demande
Vendeur : AHA-BUCH GmbH, Einbeck, AllemagneAHA-BUCH GmbH
Contacter le vendeurVendeur avec une évaluation de 5 étoilesEtat: Neuf
EUR 294,43
EUR 35,00 expéditionExpédition depuis Allemagne vers Etats-UnisQuantité disponible : 2 disponibles
Taschenbuch. Etat : Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Gene and cell therapy is entering a new phase, one where artificial intelligence is bringing precision and predictability to editing systems that were once largely trial-and-error. From CRISPR-Cas genome editing to emerging techniques like epigenome modulation and mitochondrial genome correction, machine learning and deep learning are increasingly guiding how these tools are designed and scaled. AI is helping minimize off-target effects, improve manufacturing predictability, and build in the kind of explainability and bias mitigation that safety and regulatory approval demand. As these technologies move closer to widespread clinical use, the field needs a framework that ties computational innovation directly to therapeutic application, rather than treating AI and biomedicine as separate conversations. This convergence of computational innovation and biological engineering marks one of the most consequential shifts in modern therapeutic science. AI-Driven Innovations in Genome, Epigenome, and Mitochondrial Therapies provides state-of-the-art, data-driven methodologies for designing, optimizing, and validating safer, more precise, and scalable gene and cell therapies. By connecting concrete biomedical applications with benchmarked computational pipelines and structured frameworks for transparent, accountable AI governance, this book equips researchers and practitioners to navigate discovery, preclinical validation, clinical translation, and lifecycle risk management. Covering topics such as genome-enabled precision wound care, mitochondrial mutation detection, and mitochondrial editing, this book is an excellent academic resource for graduate and doctoral students, biomedical researchers, AI and machine learning specialists, bioinformaticians, regulatory affairs professionals, policymakers, and more.…

- Couverture souple
- impression à la demande
Vendeur : preigu, Osnabrück, Allemagnepreigu
Contacter le vendeurVendeur avec une évaluation de 5 étoilesEtat: Neuf
EUR 275,60
EUR 70,00 expéditionExpédition depuis Allemagne vers Etats-UnisQuantité disponible : 5 disponibles
Taschenbuch. Etat : Neu. AI-Driven Innovations in Genome, Epigenome, and Mitochondrial Therapies | Divya Andy (u. a.) | Taschenbuch | Englisch | 2026 | IGI GLOBAL SCIENTIFIC PUBLISHING | EAN 9798260001622 | Verantwortliche Person für die EU: Libri GmbH, Europaallee 1, 36244 Bad Hersfeld, gpsr[at]libri[dot]de | Anbieter: preigu Print on Demand. …

- Couverture rigide
- impression à la demande
Vendeur : AussieBookSeller, Truganina, VIC, AustralieAussieBookSeller
Contacter le vendeurVendeur avec une évaluation de 5 étoilesEtat: Neuf
EUR 329,25
EUR 33,56 expéditionExpédition depuis Australie vers Etats-UnisQuantité disponible : 1 disponible
Hardcover. Etat : new. Hardcover. Gene and cell therapy is entering a new phase, one where artificial intelligence is bringing precision and predictability to editing systems that were once largely trial-and-error. From CRISPR-Cas genome editing to emerging techniques like epigenome modulation and mitochondrial genome correction, machine learning and deep learning are increasingly guiding how these tools are designed and scaled. AI is helping minimize off-target effects, improve manufacturing predictability, and build in the kind of explainability and bias mitigation that safety and regulatory approval demand. As these technologies move closer to widespread clinical use, the field needs a framework that ties computational innovation directly to therapeutic application, rather than treating AI and biomedicine as separate conversations. This convergence of computational innovation and biological engineering marks one of the most consequential shifts in modern therapeutic science. AI-Driven Innovations in Genome, Epigenome, and Mitochondrial Therapies provides state-of-the-art, data-driven methodologies for designing, optimizing, and validating safer, more precise, and scalable gene and cell therapies. By connecting concrete biomedical applications with benchmarked computational pipelines and structured frameworks for transparent, accountable AI governance, this book equips researchers and practitioners to navigate discovery, preclinical validation, clinical translation, and lifecycle risk management. Covering topics such as genome-enabled precision wound care, mitochondrial mutation detection, and mitochondrial editing, this book is an excellent academic resource for graduate and doctoral students, biomedical researchers, AI and machine learning specialists, bioinformaticians, regulatory affairs professionals, policymakers, and more. This item is printed on demand. Shipping may be from our Sydney, NSW warehouse or from our UK or US warehouse, depending on stock availability.…

- Couverture rigide
- impression à la demande
Vendeur : preigu, Osnabrück, Allemagnepreigu
Contacter le vendeurVendeur avec une évaluation de 5 étoilesEtat: Neuf
EUR 317,35
EUR 70,00 expéditionExpédition depuis Allemagne vers Etats-UnisQuantité disponible : 5 disponibles
Buch. Etat : Neu. AI-Driven Innovations in Genome, Epigenome, and Mitochondrial Therapies | Divya Andy (u. a.) | Buch | Englisch | 2026 | IGI GLOBAL SCIENTIFIC PUBLISHING | EAN 9798260001615 | Verantwortliche Person für die EU: Libri GmbH, Europaallee 1, 36244 Bad Hersfeld, gpsr[at]libri[dot]de | Anbieter: preigu Print on Demand.…

- Couverture rigide
- impression à la demande
Vendeur : AHA-BUCH GmbH, Einbeck, AllemagneAHA-BUCH GmbH
Contacter le vendeurVendeur avec une évaluation de 5 étoilesEtat: Neuf
EUR 346,30
EUR 42,83 expéditionExpédition depuis Allemagne vers Etats-UnisQuantité disponible : 2 disponibles
Buch. Etat : Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Gene and cell therapy is entering a new phase, one where artificial intelligence is bringing precision and predictability to editing systems that were once largely trial-and-error. From CRISPR-Cas genome editing to emerging techniques like epigenome modulation and mitochondrial genome correction, machine learning and deep learning are increasingly guiding how these tools are designed and scaled. AI is helping minimize off-target effects, improve manufacturing predictability, and build in the kind of explainability and bias mitigation that safety and regulatory approval demand. As these technologies move closer to widespread clinical use, the field needs a framework that ties computational innovation directly to therapeutic application, rather than treating AI and biomedicine as separate conversations. This convergence of computational innovation and biological engineering marks one of the most consequential shifts in modern therapeutic science. AI-Driven Innovations in Genome, Epigenome, and Mitochondrial Therapies provides state-of-the-art, data-driven methodologies for designing, optimizing, and validating safer, more precise, and scalable gene and cell therapies. By connecting concrete biomedical applications with benchmarked computational pipelines and structured frameworks for transparent, accountable AI governance, this book equips researchers and practitioners to navigate discovery, preclinical validation, clinical translation, and lifecycle risk management. Covering topics such as genome-enabled precision wound care, mitochondrial mutation detection, and mitochondrial editing, this book is an excellent academic resource for graduate and doctoral students, biomedical researchers, AI and machine learning specialists, bioinformaticians, regulatory affairs professionals, policymakers, and more.…